Skip to content

The effect of real oat bread with barley bread on serum glucose and lipid Levels in dyslipidemia and type II diabetes

Comparison of the effect of real oat bread with "oat bread" offered in Tehran on serum glucose and lipid profile in dyslipidemics and type II diabetics

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT138711071597N1
Enrollment
Unknown
Registered
2010-01-04
Start date
2008-11-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Diabetes. Condition 2: Dyslipidemia. Non-insulin-dependent diabetes mellitus, Malnutrition-related diabetes mellitus Pure hypercholesterolaemia, Other hyperlipidaemia, Hyperlipidaemia, unspecified, Lipoprotein deficiency, Other disorders of lipoprotein metabolism, Disorder of lipoprotein metabolism, unspecified

Interventions

Intervention 1: 250 g daily oat bread to patients within 3 weeks during the related phase of study consumed during the day and different meals. Intervention 2: 250 g daily barley bread to patients wit
250 g daily barley bread to patients within 3 weeks during the related phase of study consumed during the day and different meals.
250 g daily oat bread to patients within 3 weeks during the related phase of study consumed during the day and different meals.

Sponsors

National Nutrition & Food Technology Research Institute of IRAN
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with Fasting blood glucose > 126 mg/dl and at least one of lipids profile out of normal range Exclusion criteria: Patients with Cardiovascular and other systemic diseases and IDMM patients taking insulin

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Serum glucose levels. Timepoint: 0, 10 days after intervention. Method of measurement: Taking 5 ml fasting venous blood sample, Centrifuging samples, determining serum glucose by glucose oxidase using Auto analyzer.;Serum insuline levels. Timepoint: 0, 10 days after intervention. Method of measurement: Taking 5 ml fasting venous blood sample, Centrifuging samples, determining serum Insulin levels using Radioimmunoassay.

Secondary

MeasureTime frame
Fasting serum insulin levels. Timepoint: 0, 10, 21 days after intervention. Method of measurement: Taking 5 ml fasting venous blood sample, Centrifuging samples, determining serum Insulin levels using Radioimmunoassay.;Serum lipid profiles. Timepoint: 0, 10, 21 days after intervention. Method of measurement: Taking 5 ml fasting venous blood sample, Centrifuging samples, determining serum lipid profiles using Auto analyzer.;Insulin resistance. Timepoint: 0, 10, 21 days after intervention. Method of measurement: Computing insulin resistance using HOMA: (FBS*FIns)/22.5.

Countries

Iran (Islamic Republic of)

Contacts

Public Contact?Shajieh Najar-Safari

Deputy for Food and Drug – Shahid Beheshti University of Medical Sciences

shajieh_s@yahoo.com+98 21 8874 5315

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026